|
Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: A possible challenge to elimination program in India
VNR Das1, K Pandey1, D Singh2, C Forwood3, CS Lal4, P Das2
1 Department of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, India
2 Department of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, India
3 Médecins Sans Frontières, Sadar Hospital, Vaishali, India
4 Department of Biochemistry, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, India
Correspondence Address:
K Pandey
Department of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna
India
We report two cases, one male (33 years) and a female (14 years), that developed Post-Kala-azar Dermal Leishmaniasis (PKDL) after successful treatment for visceral leishmaniasis (VL) or Kala-azar with AmBisome, the lipid complex of Amphotericin B. Both cases presented with hypo-pigmented macular lesions all over the body. The patients responded well to AmBisome after treatment with three courses. This first ever case report from India indicates that possibly there is no effective drug for VL until date, which can prevent post-treatment development of PKDL.
How to cite this article:
Das V, Pandey K, Singh D, Forwood C, Lal C S, Das P. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: A possible challenge to elimination program in India.J Postgrad Med 2013;59:226-228
|
How to cite this URL:
Das V, Pandey K, Singh D, Forwood C, Lal C S, Das P. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: A possible challenge to elimination program in India. J Postgrad Med [serial online] 2013 [cited 2023 Sep 23 ];59:226-228
Available from: https://www.jpgmonline.com/article.asp?issn=0022-3859;year=2013;volume=59;issue=3;spage=226;epage=228;aulast=Das;type=0 |
|
